Feline Leukaemia Virus (FeLV) is a contagious retrovirus from the Mammalian Type-C group, which is endemic in many areas of the world. The prevalence of FeLV is particularly high among dense populations.
Transmission occurs essentially by contact, mainly through saliva or nasal secretions and by biting or licking. Clinically healthy persistantly viraemic cats are known as a major source of the virus.

Infection is characterised by the development of a viraemia which can be followed by seroconversion with elimination of the pathogen. Infected cats may also present a chronic, persistent viraemia which will lead to the development of both proliferative syndromes like lymphosarcoma or leukaemia and non-proliferative syndromes such as anaemia or immunosuppression, followed by death at short or middle term.

Diagnosis of FeLV infection is generally performed by the detection of a viral antigen from the core protein, p27, which is produced in high quantities in viraemic cats.
Feline Immunodeficiency Virus (FIV) is a lentivirus of worldwide distribution, first isolated in 1986 from several cats exhibiting signs of immunodeficiency. Prevalence rates vary from less than 1% to more than 20%, depending on the cat population (sex, age, behaviour), health status, and geographical area.

FIV is most commonly transmitted by biting. The infection is firstly expressed by a transient primary illness lasting several weeks, followed by a long period of apparent normal health which precedes a terminal immunodeficiency phase characterised by ailments such as generalised lymphadenopathy, stomatitis, gastro-enteritis, anaemia and neurological disorders. Affected cats will finally die from the development of a variety of secondary opportunistic infections or tumours.

Infection by FIV is generally accompanied by a rapid rise of antibody levels, particularly those directed against the transmembrane protein of the virus, gp40. The presence of anti-gp40 antibodies indicates that the cat has been exposed to the virus, even in the case of complete absence of symptoms.

Categories: , Brand:


WITNESS® FeLV-FIV test is indicated for use when history and/or clinical signs may suggest an infection by feline retroviruses. It will also be particularly recommended prior to an FeLV vaccination, especially in cats belonging to an at risk population.



WITNESS® FeLV-FIV is a simple test based on Rapid Immuno Migration (RIMTM) technology.
FeLV antigen is detected using antibodies directed against the circulating p27 capside protein.
The detection of FIV is based on the presence of antibodies against the transmembrane region of the virus, using a synthetic peptide from the gp40 protein.
In both cases, sensitised colloidal gold particles will form a complex with either the p27 antigen (FeLV) or antibodies (FIV) present in the sample.

The formed complexes migrate along the strips. The complexes are then captured on a sensitised reaction line where their accumulation causes the formation of a clearly visible pink band.
Control bands located at the end of the reading windows (3) ensure that the test was performed correctly.



• The test can be performed on unclotted whole blood anticoagulated with EDTA or heparin, serum or plasma.
• Samples should always be collected with a sterile needle and syringe.
• Haemolysis does not significantly interfere with the test, but strongly haemolysed samples may partly obscure a weak positive band.



Anticoagulated whole blood samples should preferably be tested immediately after collection but not longer than 4 hours after collection, if stored at room temperature.
If testing is further delayed, samples should be kept refrigerated (+2°C and 8°C) for up to 4 days.
For prolonged storage, samples (serum and plasma only) should be kept frozen (-20°C).



A. 21/05/1o pouches, each containing 1 test device and desiccant

B. 1 buffer dropper bottle (of 2.8 ml).

C.  Instructions for use.

D. 2/5/10 pipettes